emergency department. They identified 13 independent risk factors and combined these into an overall score, the Multiple Estimation of risk based on the Emergency department Spanish Score In patients with AHF (MEESSI-AHF). They found that this score was an excellent predictor of 30-day mortality. Although their investigation has been valuable, some methodological issues need to be addressed.
First, scientists usually use combined outcomes, such as all-cause mortality, to improve the power of statistical tests. However, the authors mostly neglect the main assumption of these outcomes, which can lead to biased results. The relationship between given independent variable and all-cause mortality can be assessed when the strength and direction of relationships between the previously mentioned exposure and cause-specific mortalities are homogeneous. Otherwise, the estimated effect size may be over-or underestimated or even disappear (2) . Because this assumption is hardly established in the literature, Richardson and associates have proposed a robust model-hierarchical regression-that assesses the relationship between a given independent variable and cause-specific mortality in studies with small sample sizes (2) .
Second, Miró and colleagues assessed certain independent variables in their study. However, those that vary by time, such as systolic blood pressure and potassium levels, were considered fixed variables, which is problematic. To address this problem, the authors use such methods as generalized estimating equation and random-effect models, which are not efficient and provide biased effect size estimates (3) . In 2017, Mansournia and coworkers proposed new methods, including the parametric g-formula and g-estimation, that can efficiently adjust for time-varying confounders and provide valid effect size estimates for time-varying exposures of interest (3) .
Finally, Miró and colleagues provided c-statistics for the full MEESSI-AHF model and alternative models in Appendix Table 3 of their article, but the statistical differences between these statistics have not been examined. The parsimonious model, the model with lower parameters and higher predictive performance, is preferred in epidemiologic studies (4, 5) . We suggest that the authors examine the statistical differences between the various models and select the more parsimonious one that does not statistically differ from other models.
The take-home message is that advanced statistical methods can be used to assess the association between a given risk factor and cause-specific mortality. Sophisticated statistical methods have also recently been suggested to provide valid effect size estimates for the time-varying exposures and to adjust time-varying confounders efficiently.
IN RESPONSE:
We appreciate Dr. Safiri and colleagues' interest, but their points do not seem relevant.
First, all-cause mortality over a short period (we chose 30 days) from the time of emergency department admission with acute heart failure is of key interest in assessing a patient's severity and prognosis. Short-term all-cause mortality has also been the primary or key secondary end point selected in many major trials and registries for assessing the prognosis of patients with acute heart failure (1-5). To call it a "combined outcome" misses the point.
Second, the concept of time-varying variables is irrelevant because we need rapid prediction from the moment of patient admission. We therefore chose the first systolic blood pressure and potassium measurements after arrival at the emergency department (the same principle was applied to all variables included in the MEESSI-AHF).
Finally, the determination of a parsimonious model is not relevant for the alternatives that we presented. We gave 7 alternative model options in order to facilitate individual patient prediction when 1 or more of 3 predictors (the Barthel index score, troponin level, or N-terminal pro-B-type natriuretic peptide level) is unavailable. To remove any of them involves a substantial (but slight) loss of statistical efficiency, so the best MEESSI-AHF model is the full one when all 13 independent risk factors are available. (2) . The authors contend that the latter's estimation method overstates undiagnosed diabetes because it makes the diagnosis on the basis of a single blood draw rather than performing a confirmatory blood test on a different day, as recommended by the American Diabetes Association (3) and the American Association of Clinical Endocrinologists (4).
Ó scar Miró , PhD
Data from NHANES only contain information from a single blood draw. However, NHANES does include data from both hemoglobin A 1c (HbA 1c ) and fasting glucose tests. The authors therefore propose a definition of "confirmed undiagnosed diabetes" that includes only those NHANES participants who have elevated levels of HbA 1c (≥6.5%) and fasting glucose (≥7.0 mmol/L [≥126 mg/dL]). They suggest that this approach to diagnosis is "in line with clinical guidelines" and avoids the overestimation involved in relying on a single HbA 1c or fasting glucose measurement for diagnosis.
Patients whose first test results are elevated may not have elevated results on confirmatory testing. According to Selvin and colleagues, the use of results from a single HbA 1c or fasting glucose test without a confirmatory test overestimates diabetes diagnoses by 151%. A key difference between the approach recommended by the authors and that recommended by the American Diabetes Association and American Association of Clinical Endocrinologists screening guidelines is that the latter recommend diagnosing diabetes by fasting glucose or HbA 1c testing followed by a confirmatory test using the same study used initially. The American Diabetes Association and American Association of Clinical Endocrinologists define those with elevated results on either test, with confirmationnot only those with elevated results on both studies-as having diabetes.
Cowie and associates (5) also used NHANES data. They showed that only a few participants with undiagnosed diabetes had elevated results on both HbA 1c and fasting glucose testing compared with those who had elevated results on either test alone, with 133% more participants being diagnosed with diabetes when using the latter method (reference 5 and Figure 1 
Should HbA 1c and fasting glucose levels from a single blood sample be used to diagnose diabetes? Many physicians already order both of these tests at the same time in at-risk patients. Using a combination of fasting glucose and HbA 1c levels from a single visit to diagnose diabetes may offer tremendous utility. Persons with elevated HbA 1c and fasting glucose levels are at high risk for future complications. Treatment decisions are often made on the basis of HbA 1c levels, with 7% or higher being a common threshold for pharmacotherapy. A scenario in which the HbA 1c level exceeds 7% but the fasting glucose level is less than 7.0 mmol/L (126 mg/dL) is uncommon (0.06% of adults in the United States fit this description). Furthermore, substantial discordance (in either direction) is informative and suggests, for example, a sample processing problem or health condition that may warrant follow-up.
Clear guidance on how to use the combination of these tests, including whether a diagnosis can be made on the basis of a combination of fasting glucose and HbA 1c levels measured in a single blood sample, is needed. Hepatitis B Vaccination, Screening, and Linkage to Care TO THE EDITOR: Abara and colleagues' (1) guideline on screening and vaccination for hepatitis B virus (HBV) infection is welcome. However, I am concerned that the authors did not mention the potential confounding effect of recent immunoglobulin therapy on serologic tests.
As we have described (2), passive transfer of hepatitis B antibodies is extremely common. In our cohort of patients receiving immunoglobulin therapy, at baseline 11.3% tested positive for hepatitis B surface antibody and just 1 patient had equivocal results for hepatitis B core antibody. After a median of 2 years of treatment, all patients tested positive for hepatitis B surface antibody, whereas 46.3% and 12.5% tested positive and had equivocal results for hepatitis B core antibody, respectively. These changes took place despite most patients receiving only replacement doses of immunoglobulin and being tested at IgG trough levels (immediately before infusion).
Immunoglobulin therapy is administered relatively rarely. However, some risk groups identified in Abara and colleagues' guideline are substantially more likely than the general population to receive immunoglobulin therapy, especially patients requiring immunosuppressive treatment (3) and those with abnormal results on liver function tests (4) .
False-positive results on serologic studies from passive transfer of antibody could have 2 major consequences. Detection of hepatitis B surface antibody after recent immunoglobulin therapy may falsely reassure clinicians that vaccination is not required when the patient may actually be at risk after elimination of the infused antibody (assuming that immunoglobulin therapy is not continuing indefinitely). As an alternative, the detection of hepatitis B core antibody may result in patients being told that they have evidence of an infection that is usually sexually acquired, which will create anxiety and unnecessary screening of partners; in certain circumstances (for example, with concomitant rituximab therapy), patients may even be started on prophylactic antiviral therapy.
I strongly encourage Abara and colleagues to consider in their guideline recent immunoglobulin therapy when advising on the timing and interpretation of serologic studies for HBV as a screen for prior infection or immunity. I also suggest to all clinicians that the results of these studies be checked before immunoglobulin therapy is begun to minimize risk for subsequent misleading results. TO THE EDITOR: Abara and colleagues' (1) guideline highlights the suboptimal rates of HBV screening and treatment in the United States. The authors note that many barriers prevent patients with HBV infection from receiving treatment but state that "linkage to care ensures that patients with chronic HBV infection receive treatment when they become eligible." Although linkage to care is a crucial component of HBV management, our experience has been that it is not sufficient to ensure treatment. High prescription drug costs are a substantial system-level barrier that must be considered when caring for patients with HBV infection in the United States.
The national average drug acquisition costs for a 30-day prescription of the 3 first-line drugs recommended for the treatment of chronic HBV infection are $99 for 0.5-mg tablets of entecavir, $93 for 300-mg tablets of tenofovir disoproxil fumarate, and $1032 for 25-mg tablets of tenofovir alafenamide. The high cost of these antimicrobial drugs is a problem not unique to the HBV drug market (2) .
Because a typical treatment course generally exceeds 1 year (and is often lifelong), therapy with tenofovir disoproxil fumarate or tenofovir alafenamide can be cost-prohibitive. Although the price of the former has decreased with generic competition (as occurred with entecavir) (3), additional generic entry may be required before the cost incurred by patients substantially decreases (4). Until then, our experience has been that-regardless of insurance status-HBV treatment is often unaffordable for patients without access to discount programs. Patient assistance programs unfortunately are not easily navigated, particularly for nonnative English speakers, who comprise a substantial portion of those infected with HBV in the United States. Successful navigation of these programs thus frequently requires dedicated support staff to help patients obtain assistance (5) .
In summary, although we agree that linkage to care is a crucial component of hepatitis B management, cost of treatment must be considered as a key systems barrier for patients with HBV infection in the United States. Successfully navigating this barrier requires a well-funded clinic and dedicated staff willing and able to work closely with patients to ensure that treatment is not unnecessarily delayed and can be continued without lapses.
IN RESPONSE:
We agree with Dr. Lowe that passive transfer of hepatitis B surface antibodies or hepatitis B core antibodies after immunoglobulin therapy can confound the interpretation of serologic tests for HBV and should be considered when the results of the screening tests for this condition are being interpreted. The Centers for Disease Control and Prevention thus recommends waiting 6 months after administration of this therapy before measuring hepatitis B surface antibody titers in persons who received postexposure prophylaxis (1) . In general, immunoglobulin therapy is administered relatively rarely (2) . However, it is more commonly used in patients requiring immunosuppressive therapy (2), who are 1 of the risk groups for whom we recommend HBV screening (3). Table 3 of our guideline further describes the interpretation of serologic tests for HBV. We state that the presence of isolated hepatitis B core antibodies could be due to a false-positive result (for example, passive antibody transfer after immunoglobulin administration) and recommend repeated or serial testing in these cases. Repeated testing after immunoglobulin therapy or serologic testing of an archived donor sample can help distinguish between passive transfer of HBV antibodies and other causes.
We concur with Dr. Alpern and colleagues that prescription drug costs for the treatment of chronic HBV infection represent individual-and system-level barriers to linkage to HBVdirected treatment and care. As they correctly note, the cost of a 30-day prescription for treatment of chronic infection may exceed $2000. However, because both entecavir and tenofovir disoproxil fumarate will become generic, these prices will probably decrease. Patients with chronic infection who are uninsured or underinsured are unlikely to receive the treatment or medical care that they need (4). Furthermore, unlike the Ryan White HIV/AIDS Program that supports HIV treatment and care for un-or underinsured HIV-infected persons, no such program is available for patients with chronic HBV infection. These challenges, coupled with others discussed in the guideline, can hinder linkage to care or complicate consistent care. Nonetheless, from a societal perspective, we presented data showing that hepatitis B screening and linkage to care and vaccination programs are cost-effective (5). Efforts to improve linkage to care must target individual-, clinician-, and system-level barriers to ensure that all patients with chronic infection receive timely and consistent treatment and care.
IN RESPONSE: Dr. Mossad raises an important question about integrating consulting physicians in interdisciplinary rounds and accurately enumerates reasons why physical integration is usually impractical. Here, we offer additional considerations.
First, consistent start times and structure are critical to the success of interdisciplinary rounds and therefore must be driven by the synchronized workflows of unit-based physicians and staff.
Second, if specialists lack training and practice in interdisciplinary rounds, they may adversely affect efficiency and effectiveness.
Finally, integrating the inputs of specialists rather than the specialists themselves is often sufficient.
The most viable approach is to treat the inputs of consulting physicians like any other data that should be shared during interdisciplinary rounds: The physician leading rounds should convey these inputs as part of the structured update and include specific recommendations as part of the proposed plan. We believe that consulting physicians can contribute substantially to effectiveness and efficiency by actively pushing their inputs to the attending physician through faceto-face communication, the telephone, text, or video chat-or even indirectly via the chart-ahead of interdisciplinary rounds.
We share Dr. Mossad's sense that static virtual inputs via the electronic health record do not deliver enough value to supersede dynamic exchanges that allow for questions or clarifications. However, we have been impressed with how smartphone-based video chats allow remote family members or loved ones to attend virtually so they can hear, be heard, and positively influence interdisciplinary rounds. ANNALS CME/MOC Annals of Internal Medicine offers a convenient way to fulfill both your CME and MOC requirements. Readers can complete the CME quizzes that accompany many Annals articles or document how an article you read with the "Eligible for CME Point-of-Care" label impacted your practice.
Successful completion of these CME activities enables participants to earn MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Visit www.annals.org/cme for more information.
